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of Paravalvular Prosthetic Regurgitation
Paul Sorajja, MD,* Allison K. Cabalka, MD,† Donald J. Hagler, MD,† Charanjit S. Rihal, MD*
Rochester, Minnesota
Objectives The goal of this study was to determine the long-term clinical efficacy of percutaneous repair of paravalvular
prosthetic regurgitation.
Background Percutaneous repair has emerged as an effective therapy for patients with paravalvular prosthetic regurgitation.
Methods We retrospectively identified 126 patients who underwent catheter-based treatment of symptomatic prosthetic
paravalvular regurgitation. Patients were contacted for symptoms, clinical events, and vital status.
Results The 3-year estimate for survival was 64.3% (95% confidence interval: 52.1% to 76.8%). Mortality occurred due
to cardiac, noncardiac, and unknown causes in 9.5%, 7.1%, and 5.6% of patients, respectively. Among survivors,
72% of patients who had presented with heart failure were free of severe symptoms and need for cardiac sur-
gery. Severity of residual regurgitation was not related to overall survival but was an important determinant of
other clinical events. For those with no, mild, or moderate or severe residual regurgitation, 3-year estimate of
survival free of death or need for surgery was 63.3%, 58.3%, and 30.3% (p  0.01), respectively.
Conclusions Percutaneous repair of paravalvular prosthetic regurgitation can lead to durable symptom relief in selected pa-
tients. Nonetheless, mortality remains significant in symptomatic patients with paravalvular prosthetic regurgita-
tion. Long-term clinical efficacy is highly dependent on residual regurgitation. (J Am Coll Cardiol 2011;58:
2218–24) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.041w
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iParavalvular prosthetic regurgitation occurs in 8% to 18% of
patients after heart valve surgery (1). For symptomatic patients,
repeat surgery has been the traditional treatment of paravalvu-
lar prosthetic regurgitation, but it is associated with high
operative risk and variable results (2,3). Recently, percutaneous
treatment of paravalvular prosthetic regurgitation has emerged
as a less invasive alternative, with feasibility demonstrated in
early studies (4,5). However, comprehensive data on the
long-term outcome of percutaneous repair are lacking, leading
to uncertainty regarding its clinical efficacy.
Accordingly, we examined the long-term outcome of
percutaneous repair of paravalvular prosthetic regurgitation
in a large, consecutive cohort of patients.
Methods
Study population. The Mayo Clinic Institutional Review
Board approved the present investigation.
From the *Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic
College of Medicine, Rochester, Minnesota; and the †Division of Pediatric Cardi-
ology, Mayo Clinic College of Medicine, Rochester, Minnesota. All authors have
reported that they have no relationships relevant to the contents of this paper to
disclose.t
Manuscript received June 12, 2011; revised manuscript received July 15, 2011,
accepted July 19, 2011.We retrospectively identified all 136 patients who under-
went percutaneous repair of paravalvular prosthetic regurgita-
tion at the Mayo Clinic (Rochester, Minnesota) before January
20, 2011. Each patient had met the following criteria for
percutaneous repair: 1) severe dyspnea or clinically significant
hemolytic anemia; 2) moderately severe or severe paraval-
vular prosthetic regurgitation; 3) no active endocarditis; and
4) provision of informed consent. Clinically significant hemo-
lytic anemia was defined as symptomatic anemia (hemoglobin
13 g/dl in women or15 g/dl in men) requiring transfusion,
ith laboratory evidence of intravascular hemolysis. Informed
onsent entailed a detailed discussion and understanding of the
isks associated with complex catheter techniques (e.g., trans-
eptal access, apical puncture), the off-label use of device
ccluders, the unknown clinical efficacy of the procedure, and
onsideration of alternative therapies, including open surgical
orrection. There were no specific anatomic criteria for exclu-
ion, although all patients had paravalvular regurgitation in-
olving less than one-third of the sewing ring. Of these 136
atients, 10 declined use of their medical records for research.
he remaining patients consented to participate in accordance
ith Minnesota law, forming the present cohort. This cohort
ncludes patients examined in our initial experience with this
herapy and in our previous imaging review (4,6,7).
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November 15, 2011:2218–24 Long-Term Paravalvular Leak RepairPercutaneous repair. Percutaneous repair of paravalvular
rosthetic regurgitation was performed with techniques de-
cribed previously (4,6,7). Single- or multiple-device occluders
ere placed under fluoroscopic and echocardiographic guid-
nce with care to minimize risk of prosthetic impingement and
evice embolization. Patients were continued on previously
rescribed antiplatelet and anticoagulant therapy without ad-
itional medical prescription. Aortic and mitral paravalvular
egurgitation, before and immediately after the procedure, was
raded semiquantitatively using Doppler echocardiography
nd color-flow imaging (grade I, mild; grade II, moderate;
rade III, moderate to severe; and grade IV, severe) by
chocardiographers experienced in the intraoperative assess-
ent of mitral valve repair and regurgitation (8). In equivocal
ases, angiography was used with grading according to Sellers
riteria (9).
linical follow-up. Patients were contacted by mailed ques-
ionnaire and telephone survey to determine occurrence of
dverse clinical events, symptoms, and vital status. Sudden
ardiac death was defined as instantaneous and unexpected
eath with or without documented ventricular fibrillation
ithin 1 hour after a witnessed collapse, or nocturnal death in
atients who previously were in stable clinical condition, or
ppropriate discharge of an implanted defibrillator (4). Occurrence
f stroke was defined according to standard criteria (10).
ata analysis. Survival estimates with 95% confidence inter-
als (CIs) were calculated for study endpoints using the
aplan-Meier method. To examine the impact of residual
egurgitation on outcome, patients were grouped according to
o, mild, and moderate or severe residual paravalvular pros-
hetic regurgitation for comparisons. Cox regression analyses
ith stepwise techniques were used to identify variables inde-
endently associated with the endpoints that were incorporated
nto the final models. Variables included in the model were
ge; male sex; presenting symptoms (heart failure [HF] or
emolytic anemia); treated prosthesis location (aortic or mi-
ral); prosthesis type (mechanical or biologic); history of coro-
ary artery disease, peripheral vascular disease, hypertension,
trial fibrillation, chronic obstructive pulmonary disease, prior
troke, creatinine clearance 60 ml/min, and coronary artery
ypass graft; left ventricular ejection fraction, right ventricular
ystolic pressure, and medication use (beta-receptors,
ngiotensin-converting enzyme inhibitor, or angiotensin re-
eptor blocker). For symmetrically distributed data, analysis of
ariance was used for comparison; the Kruskal-Wallis test was
sed in the event of skewed data. Contingency tables were
nalyzed for association with a chi-square or Fisher exact tests.
tatistical significance was inferred at p  0.05.
esults
atients. Mean age was 67  12 years, and 53.2% were
en (Table 1). HF was the most common indication for the
rocedure, occurring in 117 patients (92.9%). Transfusion-
ependent, hemolytic anemia was present in 37 patients
36%). Treated defects were most commonly paramitral and bnvolved mechanical prostheses.
ignificant morbidity was fre-
uent. Using the Society of Tho-
acic Surgeons’ risk calculator,
he estimated operative mortality
or open repair in the cohort was
.7  5.4% (11).
ercutaneous repair. Percutaneous repair was attempted
n a total of 154 paravalvular defects (Table 2), resulting in
o, mild, and moderate or severe residual regurgitation in 47
atients (37%), 49 patients (39%), and 30 patients (24%),
espectively. Three patients with moderate residual regur-
itation underwent a second percutaneous attempt in
ollow-up, with reduction of regurgitation in only 1 of these
atients. In 11 patients (8.7%), the procedure was unsuc-
essful due to either inability to cross the defect with wire or
elivery catheter, prosthetic leaflet impingement from the
ccluder, or persistent severe regurgitation despite device
lacement.
urvival. Median follow-up for the study patients was 11.0
onths, with a range of 1 to 85 months (mean 17  17
onths; 99% complete). No acute procedural deaths oc-
urred, but 3 deaths occurred within 30 days. Two other
atients (1.6%) suffered disabling strokes on days 4 and 9
fter their procedure. One stroke was hemorrhagic, occur-
ing while the patient was receiving heparin bridging. The
econd stroke was an embolic event.
Twenty-nine deaths occurred during follow-up (Table 3).
he most common cause of death was HF (37% of deaths),
hereas noncardiac causes accounted for 9 deaths (30% of
eaths). Three deaths resulted from perioperative compli-
ations in patients who had subsequent cardiac surgery for
ailed percutaneous repair. For the entire cohort, the esti-
ate for 3-year survival free of all-cause mortality was
4.3% (95% CI: 52.0% to 76.6%) (Fig. 1). Overall survival
id not significantly differ for patients with no (69.9% [95%
I: 51.0% to 88.8%]), mild (62.4% [95% CI: 41.6% to
3.2%]), or moderate or severe (58.1% [95% CI: 32.0% to
4.3%]) residual regurgitation, before and after multivariate
djustment.
ymptoms and clinical events. Among the 89 surviving
atients who presented with HF as the indication for the
rocedure, 64 patients had no or only mild exertional
yspnea. Symptom improvement was confined to those
atients who had no or only mild residual regurgitation
Fig. 2).
In the overall population, 2 patients had acute device
mbolization; both occluders immediately were retrieved
uccessfully percutaneously. In follow-up, there were no
ncidences of late embolization, infection, or other device
omplications. Hemolytic anemia persisted in 14 of 29
urvivors. There was no relation between the degree of
esidual regurgitation and incidence of persistent hemolytic
nemia. Compared with other patients, those with hemo-
ytic anemia had poorer survival and need for cardiac surgery
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failureefore and after multivariate adjustment (Fig. 3).
horacic
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Long-Term Paravalvular Leak Repair November 15, 2011:2218–24Two patients underwent cardiac surgery after failed
percutaneous repair during the same hospitalization. In
addition, 18 patients subsequently underwent cardiac sur-
gery for either failed percutaneous repair or significant
residual regurgitation in follow-up. Overall, 3-year estimate
for survival free of any death or need for cardiac surgery was
53.5% (95% CI: 41.4% to 65.6%). The degree of residual
regurgitation significantly affected the need for cardiac
surgery. For patients with no, mild, and moderate or severe
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
All Patients
(N  126)
Age (yrs) 67 13
Male 67 (53.2)
Presenting symptoms
Heart failure 117 (92.9)
Hemolytic anemia 37 (29.4)
Right heart failure 15 (11.9)
Treated prosthesis type
Aortic 27 (21.4)
Mitral 99 (78.5)
Bioprostheses 49 (38.9)
Mechanical prostheses 77 (61.1)
Time of implant to percutaneous repair (mos) 67 75
Medical history
Coronary artery disease 40 (31.7)
Peripheral vascular disease 10 (7.9)
Hypertension 63 (50.0)
Atrial fibrillation 69 (54.7)
Chronic obstructive pulmonary disease 17 (13.4)
Previous stroke 28 (22.2)
Creatinine clearance 60 ml/min 71 (56.3)
Congenital heart disease 2 (1.6)
Radiation heart disease 4 (3.2)
Prior procedures
2 sternotomies 70 (55.6)
Other left-sided valve replacement‡ 38 (30.1)
2 left-sided mechanical prostheses 26 (20.6)
Previous surgical leak repair 24 (19.0)
Coronary artery bypass graft 40 (31.7)
Permanent pacemaker 17 (13.5)
Implanted defibrillator 5 (4.0)
Left ventricular ejection fraction (%) 56 13
Left ventricular end-diastolic diameter (mm) 52 9
Left ventricular end-systolic diameter (mm) 36 9
Right ventricular systolic pressure (mm Hg)§ 55 18
Medications
Beta-receptor antagonists 89 (70.6)
ACE inhibitor or ARB 58 (46.0)
Diuretic 91 (72.2)
Digoxin 36 (28.6)
Warfarin 77 (61.1)
STS estimated operative mortality 6.7 5.4
Values are mean SD or n (%). *p values for all group comparisons for continuous variables were
prosthesis that was treated percutaneously. §Echocardiographic estimation.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; STS Society of Tresidual regurgitation, 3-year estimate of survival free ofdeath or need for cardiac surgery was 63.7% (95% CI: 44.5%
to 82.8%), 59.0% (95% CI: 38.2 to 79.9%), and 30.9% (95%
CI: 9.1 to 52.6%) (p  0.01), respectively (Fig. 4). These
differences in survival remained significant after multivariate
adjustment.
Discussion
The principal findings of the present investigation are: 1)
Residual Regurgitation
p Value
ne
47)
Mild
(n  49)
Moderate or Severe
(n  30)
 13 65 13 68 10 *
48.9) 30 (61.2) 14 (46.7) *
95.7) 44 (89.8) 28 (93.3) 0.52
31.9) 12 (24.4) 10 (33.3) 0.16
23.4) 2 (4.1) 2 (6.7) 0.01
12.8) 15 (31.6) 6 (20.0) 0.10
87.2) 34 (69.4) 24 (80.0) 0.10
40.4) 21 (42.8) 9 (30.0) 0.42
59.6) 21 (42.8) 21 (70.0) 0.42
 73 50 61 99 91 0.01†
36.2) 20 (40.8) 3 (10.0) 0.01
12.8) 2 (4.1) 2 (6.7) 0.28
51.1) 25 (51.0) 14 (46.7) 0.92
57.4) 26 (53.1) 16 (53.3) 0.90
14.9) 7 (14.3) 3 (10.0) 0.81
31.9) 8 (16.3) 5 (20.0) 0.13
68.1) 25 (51.0) 14 (46.7) 0.11
2.1) 1 (2.0) 0 (0) 0.49
0) 3 (6.1) 1 (3.3) 0.23
57.4) 25 (51.0) 18 (60.0) 0.88
29.7) 14 (28.6) 10 (33.3) 0.90
25.5) 9 (18.4) 5 (20.0) 0.57
21.3) 7 (14.3) 7 (23.3) 0.54
38.3) 20 (40.8) 3 (10.0) 0.01
17.0) 5 (10.2) 4 (13.3) 0.62
0) 4 (8.2) 1 (3.3) 0.12
 13 55 15 58 12 *
 11 54 9 53 7 *
 8 38 11 35 8 *
 21 52 16 59 18 *
72.3) 34 (69.4) 21 (70.0) 0.95
44.7) 21 (42.9) 16 (53.3) 0.88
70.2) 36 (73.4) 22 (73.3) 0.93
27.7) 9 (18.4) 14 (46.7) 0.03
61.7) 27 (55.1) 20 (66.7) 0.54
 5.2 6.1 6.4 6.2 4.1 *
. †p value for comparison of moderate or severe versus mild. ‡Valve replacement apart from the
Surgeons.No
(n 
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0.05percutaneous repair of paravalvular prosthetic regurgitation
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November 15, 2011:2218–24 Long-Term Paravalvular Leak Repaircan lead to durable improvement in symptoms of HF in
selected patients; 2) severity of residual regurgitation after
percutaneous repair directly affects the long-term durability
of symptom relief; and 3) significant mortality persists in
patients with symptomatic paravalvular prosthetic regurgi-
Procedural CharacteristicsTable 2 Procedural Characteristics
Characteristic All Patients (N  126) No
General anesthesia 104 (82.5)
Echocardiography
Intracardiac 15 (11.9)
Transthoracic 18 (14.2)
Transesophageal 103 (81.7)
Perivalvular defects
Number attempted 154
Periaortic 30
Perimitral left ventricle to left atrium 122
Perimitral left ventricle to right atrium 2
Total number of devices implanted 156
Patients with multiple defects closed 20
Technique used
Periaortic retrograde 30 (23.8)
Perimitral
Antegrade transeptal 98 (77.7)
Right internal jugular vein to left ventricle 2 (1.6)
Apical puncture 13 (10.3)
Transaortic exteriorization 36 (28.5)
Retrograde aortic approach 2 (1.6)
Simultaneous or anchor wire 12 (9.5)
Amplatzer occluder device type
Atrial septal occluder 12 (9.5)
Vascular Plug II 77 (61.1)
Patent ductal occluder 20 (15.8)
Ventricular septal occluder 10 (7.9)
Procedure time (min) 147 52
Fluoroscopy time (min) 56 34
Contrast used (ml) 32 49
Length of stay after procedure (days) 4.9 6.6
Values are n (%) or mean SD. Two patients received 2 different types of devices. *P value for com
variables between groups were 0.05.
Clinical EventsTable 3 Clinical Events
Event All Patients (N  126) None (n 
Death 29 (23.0) 9 (19.
Heart failure–related 11 (8.7) 2 (4.3
Sudden cardiac death 1 (0.7) 0 (0)
Noncardiac 9 (7.1) 3 (6.4
Unknown 7 (5.6) 3 (6.4
Severe symptoms* 14 (14.5) 3 (7.9
Persistent hemolytic anemia* 17 (17.7) 6 (15.
Subsequent cardiac surgery 20 (15.8) 3 (6.4
Stroke 2 (1.6) 0 (0)Values are n (%). *Percentage calculated for survivors only.tation after percutaneous repair. Our findings, which were
observed in a high-risk patient cohort, demonstrate clinical
efficacy that may reduce the need for re-operation in these
patients, in whom morbidity and the risk of open surgery
frequently is increased. Nonetheless, continued refinements
Residual Regurgitation
p Value 47) Mild (n  49) Moderate or Severe (n  30)
9.3) 38 (77.6) 24 (80.0) 0.29
.3) 9 (18.4) 4 (13.3) 0.10
2.7) 7 (14.3) 5 (16.7) 0.89
7.2) 38 (77.6) 24 (80.0) 0.45
59 40
15 8
43 32
1 0
58 34
8 6
4.9) 15 (30.6) 8 (26.7) 0.18
5.1) 34 (69.4) 24 (80.0) 0.17
.1) 1 (2.0) 0 (0) 0.45
7.0) 2 (4.1) 3 (10.0) 0.11
1.9) 10 (20.4) 11 (36.7) 0.24
.1) 1 (2.0) 0 (0) 0.45
0.6) 4 (8.2) 3 (10.0) 0.89
0.10
0.6) 4 (8.2) 3 (10.0)
5.9) 34 (69.4) 12 (40.0)
0.6) 7 (14.3) 8 (26.7)
0.6) 2 (4.1) 3 (100)
48 135 56 162 50* 0.05†
29 51 31 74 39† 0.01,† 0.003*
29 44 57 36 53† 0.004*
4.0 4.3 7.1 8.3 8.3* 0.02,† 0.003*
versus none. †P value for comparison versus mild. All other p values for comparison of continuous
Residual Regurgitation
p ValueMild (n  49) Moderate or Severe (n  30)
12 (24.5) 8 (26.7) 0.64
6 (12.2) 3 (10.0) 0.35
0.45
1 (2.0) 0 (0) 0.45
0.93
3 (6.1) 3 (10.0) 0.93
2 (4.1) 2 (6.7) 0.85
5 (13.8) 6 (27.3) 0.0001
7 (19.4) 4 (18.2) 0.21
4 (8.2) 9 (30.0) 0.0020
1 (2.0) 1 (3.3) 0.48ne (n
42 (8
2 (4
6 (1
41 (8
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Long-Term Paravalvular Leak Repair November 15, 2011:2218–24to improve procedural success are needed to enhance the
durability of its clinical efficacy.
Although percutaneous repair of paravalvular prosthetic
regurgitation was first reported nearly 2 decades ago, this
therapy only definitively emerged with recent innovations in
delivery catheter and device occluder design. Feasibility
studies, albeit mainly small case series, have demonstrated
acute procedure success occurring in 80% of treated
atients. The present investigation extends previous acute
tudies by examining the durable efficacy of percutaneous
epair of paravalvular prosthetic regurgitation. The 3-year
stimate of survival of all-cause mortality was 64.5%. Lim-
ted life expectancy after repair of paravalvular prosthetic
egurgitation also has been observed in surgical series, with
study reporting a 10-year survival of only 30%, likely
eflecting the substantial morbidity of these patients (3). In
ur series, although cardiac etiologies were the most com-
on cause of death (9.5% of total patients) and there was a
ignificant number with unknown cause (5.6%), noncardiac
auses also were frequent (7.1%), indicative of significant
omorbidity. These morbidities included high incidences of
ultiple prior sternotomies (56%), renal failure (56%),
Figure 1 Survival After Percutaneous Repair
of Paravalvular Prosthetic Regurgitation
Survival free of all-cause mortality is shown for (A) the entire patient cohort
and (B) according to degree of residual paravalvular prosthetic regurgitation.ulmonary hypertension (33%), low ejection fraction (26%),
nd previous stroke (22%).
Among survivors who had presented with HF as the
rimary indication for the procedure, 72% had clinical
mprovement with mild or no symptoms in follow-up. This
mprovement occurred with a relatively low early mortality
30-day incidence, 2.4%), and was more common in pa-
ients who had no or only mild residual regurgitation. These
ata suggest that percutaneous therapy, when successful,
ay be a viable alternative to open surgery, particularly in
atients in whom morbidity significantly increases the risk
or re-operation.
Figure 2 Symptom Improvement With Percutaneous
of Paravalvular Prosthetic Regurgitation
New York Heart Association (NYHA) functional class (open bars) at baseline
and (solid bars) at follow-up in the overall population and according to degree
of residual paravalvular prosthetic regurgitation. *p  0.05 versus baseline.
Figure 3 Outcome According to Presence
or Absence of Hemolytic Anemia
Survival free of the combined endpoint of death or need for cardiac surgery is
shown according to the presence or absence of hemolytic anemia as an indica-
tion for percutaneous repair of paravalvular prosthetic regurgitation.
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November 15, 2011:2218–24 Long-Term Paravalvular Leak RepairPercutaneous repair of paravalvular prosthetic regurgita-
tion is a challenging procedure in which complex catheter
techniques with a steep learning curve are used. Compe-
tency in the performance of these techniques, in conjunction
with care given in a multidisciplinary setting, is a key
component to acute procedural success. Importantly, the
present investigation observed a direct relation between
residual paravalvular prosthetic regurgitation and survival
free of adverse events. These data are analogous to previous
studies of native valvular disease, in which a moderate
degree of regurgitation even in an asymptomatic patient has
longitudinal implications (12).
The implications of residual regurgitation after percuta-
neous repair are significant, as current technology is not
purposefully designed for this procedure, and there is
significant potential for continued regurgitation despite
successful placement of an occluder. In the present study,
grading of residual regurgitation encompassed all visible
flow through the paravalvular defect. However, significant
residual regurgitation, when present, usually occurred jux-
Figure 4 Survival Free of Death or Need for Cardiac Surgery
Survival free of the combined endpoint of death or need for cardiac surgery is
shown for (A) the entire patient cohort and (B) according to degree of residual
paravalvular prosthetic regurgitation.taposed rather than through the device. Later in ourexperience, we incorporated newer percutaneous techniques,
such as simultaneous placement of multiple, smaller devices
for oblong defects. This approach, which was selectively
used in 12 patients, helped more fully reduce residual
regurgitation and may lead to improvement in long-term
clinical efficacy when more broadly applied in future studies.
Further study on the most appropriate antithrombotic
therapy in the use of these devices for this indication also is
required, particularly because we observed 2 major peripro-
cedural stroke events. In our practice, dual antiplatelet
therapy is empirically prescribed for up to 6 months after
device closure of atrial septal defects or patent foramen
ovale, but such therapy currently is not routinely used in
patients undergoing paravalvular leak repair.
Paravalvular prosthetic regurgitation is an established
etiology of hemolytic anemia, with early reports of this
association dating back to the 1960s (13). The present
investigation included a significant subset of patients with
transfusion-dependent, hemolytic anemia (29.4%). During
follow-up, hemolytic anemia remained in 14 of 29 survivors.
The reasons for lack of better efficacy with percutaneous
closure in these patients are not clear. The incidence of
persistent hemolytic anemia was related to severity of
residual regurgitation, but this finding could be attributable
to the relatively small patient samples. Theoretically, either
flow turbulence from an intravascular device or flow accel-
eration from reduction in regurgitant orifice size could
exacerbate hemolytic anemia. However, we observed exac-
erbation of hemolytic anemia in only 1 patient. Further
study to define the role of percutaneous repair in the
treatment of patients for this indication is needed.
Study limitations. The retrospective nature of this study
has known limitations, including potential for referral basis.
Notably, serial echocardiography was not performed, and
data on residual regurgitation at final follow-up were not
available due to the referral nature of our clinical practice.
Of note, the present investigation consists of a consecutive
cohort of patients after exclusion of patients who did not
provide informed consent for use of their medical record for
research purposes. Patient follow-up was high (99%) and
included detailed prospective examination of all adverse
clinical events, need for surgery, current symptoms, and vital
status, including cause of death when possible.
Conclusions
The present investigation demonstrated that percutaneous
repair is a viable option with the potential for durable
clinical efficacy. Percutaneous repair can be undertaken as
part of therapeutic strategy for the treatment of severely
symptomatic paravalvular prosthetic regurgitation. None-
theless, mortality remains significant after the procedure,
and the long-term efficacy is dependent on residual para-
valvular regurgitation. Further studies to refine patient
selection and improve the early technical success of the
procedure are needed.
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